AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria.

Despite diagnosis and treatment options improving for the rare kidney condition, further action is urgently required.

Updated Date: Wed, 05 Jan 2022 00:00:00 EST

Updated Date: Wed, 05 Jan 2022 00:00:00 EST

Updated Date: Wed, 05 Jan 2022 00:00:00 EST

Updated Date: Wed, 05 Jan 2022 00:00:00 EST

Updated Date: Wed, 05 Jan 2022 00:00:00 EST

AstraZeneca sells another half-million doses of its COVID-19 antibody combo to the US fkansteiner Wed, 01/12/2022 – 14:39

Long before the onset of dementia, there is evidence for increased activity of the brain’s immune system. Researchers […]

By combining information from two advanced imaging techniques with clinical data, physicians can improve their prediction of heart […]